Cancer Immunology and Immunotherapy Program

癌症免疫学和免疫治疗计划：摘要/摘要 癌症免疫学和免疫治疗计划(CII)的总体科学目标是促进 了解免疫系统和癌症之间的相互作用，以发现新的免疫策略- 以免疫疗法为基础，并减轻治疗阻力。总体而言，CII计划研究导致 免疫细胞识别肿瘤的分子基础研究进展 肿瘤为逃避免疫监视而进化的机制，微环境如何影响 肿瘤免疫应答与T细胞过继细胞基因工程技术进展 治疗。CII计划是继前一次竞争性续签后的一项新计划。HDfccc-Wide 研究计划的重新调整增加了发现科学家之间直接互动的机会 和临床研究人员在CII计划内和计划之间。会员的研究优势 包括免疫学、免疫治疗、肿瘤微环境、细胞治疗和免疫方面的专业知识 治疗抵抗力。CII计划为解决与差异相关的问题提供了一个独特的机会 在集水区的白血病、多发性骨髓瘤、淋巴瘤、黑色素瘤和肺癌，有特殊的 注意了解总体临床反应的差异以及获得新的 在这个多样化的人群中进行免疫疗法。因此，CII成员可以翻译HDfccc 将发现科学带入临床，并将临床观察带回HDfccc实验室。具体来说， CII成员进行研究，以(1)确定癌症和免疫系统之间的机制相互作用， (2)先进的治疗干预措施，以改善癌症免疫治疗的结果，以及(3)确定 癌症免疫治疗的耐药机制。

Cancer Immunology and Immunotherapy Program: Summary/Abstract The overarching scientific goal of the Cancer Immunology and Immunotherapy Program (CII) is to advance the understanding of the interplay between the immune system and cancer to discover new strategies for immune- based immunotherapies and to mitigate therapeutic resistance. Overall, CII Program research has led to advances in the understanding of the molecular basis for immune cell recognition of tumors, evasive mechanisms evolved by tumors to escape immune surveillance, how the microenvironment influences the immune response to cancer, and technological advances in genetic engineering of T cells for adoptive cell therapies. The CII Program is a new program since the prior competing renewal. The HDFCCC-wide realignment of research programs enhances opportunities for direct interaction between discovery scientists and clinical investigators within the CII Program and between programs. Research strengths of members include expertise in immunology, immunotherapy, the tumor microenvironment, cellular therapy, and immune therapeutic resistance. The CII Program provides a unique opportunity to address issues related to disparities in the catchment area in leukemia, multiple myeloma, lymphoma, melanoma, and lung cancer, with special attention placed on understanding differences in the overall clinical responses as well as access to novel immunotherapies in this diverse population. CII members are therefore positioned to translate HDFCCC discovery science into the clinic, and to bring clinical observations back to HDFCCC laboratories. Specifically, CII members conduct research to (1) define the mechanistic interplay between cancer and the immune system, (2) advance therapeutic interventions to improve outcomes with cancer immunotherapy, and (3) identify mechanisms of resistance to cancer immunotherapy.